| Literature DB >> 31453087 |
Richard Komakech1,2,3, Yong-Goo Kim2, Gilbert Motlalepula Matsabisa4, Youngmin Kang1,2.
Abstract
Chronic inflammation is one of the causes of a number of non-infectious diseases in the world. Over the years, Tamarindus indica has played fundamental roles in traditional medicine as an anti-inflammatory and analgesic drug. It is a commercialized biocompatible medicinal plant species with a wide range of therapeutic window and with suggested LD50 greater than 5000 mg kg-1 body weight when administered to the Wistar rats. This review examined the anti-inflammatory and analgesic potential and mechanism of various extracts from T. indica pulp, leaves, seeds, stem bark, and roots. The preclinical studies provided strong pharmacological evidence for the anti-inflammatory and analgesic activities of the different parts of T. indica and this may be attributed to the various bioactive compounds in it including alkaloids, flavonoids, tannins, phenols, saponins, and steroids. The anti-inflammatory and analgesic effects of the extracts from the different parts of T. indica may be due to its ability to inhibit a number of biological processes including cyclooxygenase-2 (COX-2) expression, inducible nitric oxide synthase (iNOS), 5-lipoxygenase biosynthesis, and tumor necrosis factor-α. The analgesic activity of T. indica may also be through the activation of the opioidergic mechanism at both the peripheral and central levels. Although further pre-clinical studies still need to be conducted, these results demonstrated that T. indica has potent anti-inflammatory and analgesic activities and hence provides justification for its use in traditional medicine to treat body pain and other inflammatory related diseases including arthritis and offers a basis for future clinical studies and possible drug development.Entities:
Keywords: Analgesic; Anti-inflammatory; Phytochemical; Tamarindus indica; Traditional medicine
Year: 2019 PMID: 31453087 PMCID: PMC6704379 DOI: 10.1016/j.imr.2019.07.002
Source DB: PubMed Journal: Integr Med Res ISSN: 2213-4220
Fig. 1The botanical morphology of the main features of Tamarindus indica. (a) Tamarindus indica tree growing in Eastern Uganda. (b) Greyish stem bark of T. indica. (c) Alternate, compound, opposite leaflets leaf of T. indica. (d) T. indica flowers. (e) T. indica fruits. (f) Rusty-brown pulp of T. indica. (g) Irregularly shaped, shiny, and smooth seeds of T. indica with very hard testa.
Pre-clinical Toxicological Study on the Various Parts of Tamarindus indica
| Plant part used | Extract used | Animal model | Dosage used | Type of study | Percentage survival | Overall conclusion | Reference |
|---|---|---|---|---|---|---|---|
| Pulp | Ethanolicextract | Wistar rats | 5000 mg/kg body weight | Acute toxicity | 100 | Non-toxic and considered safe | |
| Pulp | Aqueous extract | Wistar rats | 4500 mg/kg body weight | Acute toxicity | 100 | No apparent congestion and hemorrhage in gastro intestinal track and no lesions observed on the liver and kidney. | |
| Leaves | 72% (v/v) ethanolic extract | Wistar rats | 5000 mg/kg body weight | Acute toxicity | 100 | No changes in skin or pelage were observed and mucous membranes and eyes showed normal appearance and colour. | |
| Leaves | Fluid extract | Wistar rats | 2000 mg/mL body weight | Acute toxicity | 100 | No observable change in the animal's hair and skin. | |
| Stem bark | Ethanolic extract | Brine shrimp | 200 μg/mL | Acute toxicity | 13 | ||
| Pulp | Water extract | Rabbits | 100 mg/kg body weight | Sub-chronic toxicity | 100 | Enhanced performance of the liver and kidneys and increased white blood cells and red blood cells counts | |
| Pulp | Water extract | Wistar rats | 1000 mg/kg body weight | Chronic toxicity test | 100 | No abnormalities in hematology and blood biochemistry parameters. |
The Anti-inflammatory and Analgesic Activities of the Extracts from Different Parts of T. indica
| Plant part used | Extract and dosage administered | Animal model used | Pharmacological effects and conclusion | Reference |
|---|---|---|---|---|
| Stem bark | Hexane, ethyl acetate, and methanol fractions administered at 200 mg/kg body weight | Wistar rats | Inhibited the writhing response an indication of potent antinociceptive activity | |
| Pulp | Aqueous extract administered at a dose of 60, 100, 300 and 600 mg/kg | Albino mice | Exhibited an antinociceptive activity through activation of the opioidergic mechanism at both the peripheral and central levels. | |
| Seeds | Ethanolic extract administered at 25–50 mg/kg body weight | Wistar rats | Reduced the levels of pro-inflammatory mediators and arthritis-mediated cartilage and bone degradation. | |
| Petroleum Ether fraction and Ethyl acetate fractions administered at 50 and 100 mg/kg body weight | Wistar rats | Increased latency to tail flick in the tail immersion method. | ||
| Methanolic extract administered at doses of 100 mg/kg, 200 mg/kg and 400 mg/kg body weight | Wistar rats | Reduced carrageenan induced paw edema in rats an indication of potent antinociceptive activity. | ||
| Methanolic extract administered at 200 mg/kg body weight | Wistar rats | Exhibited anti-inflammatory and central analgesic activity. | ||
| Roots | Aqueous extract administered at 300 and 600 mg/kg body weight | wistar rats | Enhanced pain inhibition. | |
| Leaves | Hydro-ethanolic extract administered at 500, 750, and 1000 mg/kg body weight | Wistar rats | Enhanced anti-inflammatory and anti-nociceptive actions. | |
| Aqueous extract administered at 400 mg/kg body | wistar rats | Enhanced anti-inflammatory and anti-nociceptive activities. | ||
| Ethanolic extract administered at 400 mg/kg body | Swiss albino mice | Enhanced analgesic activity. |
The Anti-Inflammatory and Analgesic Activities of Isolated Flavonoids from Tamarindus indica
| Phytochemicals | Compound structure | Pharmacological target(s) | Overall effect (s) | Study conducted | Reference |
|---|---|---|---|---|---|
| Procyanidins | NF-κB pathways; inhibiting iNOS and COX-2 expressions. | Down regulation of inflammation and body pain | |||
| Catechin | NF-κB mitogen activated protein kinases. | Down regulation of inflammation and body pain. | |||
| Taxifolin | Inhibition of LPS-induced tumor necrosis factor-α. | Down regulation of inflammation and body pain. | |||
| Apigenin | Inhibition of NO production and iNOS, and COX-2 expression | Down regulation of inflammation and body pain. | |||
| Luteolin | Down regulation of inflammatory mediators and cytokines | Down regulation of inflammation and body pain. | |||
| Naringenin | Inhibition of the pro-inflammatory cytokines. Modulate transient receptor potential channels | Down regulation of inflammation and body pain. | |||